Personalis

Q1 FY2026 EarningsTempus AI to acquire Personalis for $16.25 per share in a deal valued at $1.5B (net of existing stakes), representing a 28% premium over the 30-day VWAP. Q2 FY26 preliminary revenue reached $22.4M, with clinical test volumes surging to 10,384, up 33% QoQ. The acquisition integrates Personalis’ MRD technology into Tempus’ AI platform, targeting a $20B market opportunity with closing expected by late 2026.